Detail Vaccination for hepatitis C virus: closing in on an evasive target (from Expert Rev Vaccines 2011, 10 (5), 659-672) Bibliografi Author: Halliday, John ; Klenerman, Paul ; Barnes, Eleanor Topik: Hepatitis C virus; Immunity; Prophylactic vaccine; T cells; Therapeutic vaccine; D seminar Bahasa: (EN )     Tahun Terbit: 2011     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: ukmss-35503.pdf (585.06KB; 0 download) Abstract Hepatitis C virus (HCV) infects more than 170 million people globally and is a leading cause of liver cirrhosis, transplantation and hepatocellular carcinoma. Current gold-standard therapy often fails, has significant side effects in many cases and is expensive. No vaccine is currently available. The fact that a significant proportion of infected people spontaneously control HCV infection in the setting of an appropriate immune response suggests that a vaccine for HCV is a realistic goal. A comparative analysis of infected people with distinct clinical outcomes has enabled the characterization of many important innate and adaptive immune processes associated with viral control. It is clear that a successful HCV vaccine will need to exploit and enhance these natural immune defense mechanisms. New HCV vaccine approaches, including peptide, recombinant protein, DNA and vector-based vaccines, have recently reached Phase I/II human clinical trials. Some of these technologies have generated robust antiviral immunity in healthy volunteers and infected patients. The challenge now is to move forward into larger at-risk or infected populations to truly test efficacy. [d seminar] Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved